论文部分内容阅读
目的:观察和分析重组人生长激素在儿童特发性矮小症患者中的临床医疗效果。方法:选择我院2013年1月至2015年1月收治的150例儿童特发性矮小症患者为研究对象,将其随机分为实验组(75例)与对照组(75例),实验组中,患者采用重组人生长激素进行治疗。对照组患者采用常规胰岛激素进行治疗。分析与研究试验对象的临床医疗情况,并且进行综合疗效评定。结果:通过比较实验组与对照组间的治疗总有效率,实验组为93.3%,而对照组仅为82.7%,实验组的患者具有明显优势,差异结果显著(P<0.05),具有统计学意义。结论:重组人生长激素对于儿童特发性矮小症患者具有很好的临床医疗效果,可以有效缓解患者的病情,在今后的儿童特发性矮小症临床治疗过程中值得参考。
Objective: To observe and analyze the clinical effect of recombinant human growth hormone in children with idiopathic short stature. Methods: A total of 150 children with idiopathic short stature admitted to our hospital from January 2013 to January 2015 were selected and randomly divided into experimental group (75 cases) and control group (75 cases), experimental group The patients were treated with recombinant human growth hormone. Patients in the control group were treated with conventional islet hormones. Analyze and study the clinical situation of the test subjects, and conduct a comprehensive evaluation of the effects. Results: By comparing the total effective rate between the experimental group and the control group, the experimental group was 93.3%, while the control group was only 82.7%. The patients in the experimental group had obvious advantages and the difference was significant (P <0.05) significance. Conclusion: Recombinant human growth hormone has a good clinical effect on idiopathic short stature in children, which can effectively relieve the patient ’s condition and is worthy of reference in the future clinical treatment of idiopathic short stature.